Physician profile
Daniel J Berger
NPI 1831166362
$3,498.04
in general payments reported to CMS, 2019-2025
30 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $793 · 2021: $458 · 2022: $105 · 2023: $464 · 2024: $539 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $522.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $462.66 | 2019-2025 | Repatha, Evenity |
| Pfizer INC. | $329.92 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $292.17 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $193.56 | 2019-2025 | |
| Mannkind Corporation | $189.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $187.34 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $145.16 | 2019-2024 | Arexvy, Shingrix |
| Abbott Laboratories | $142.47 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $136.74 | 2019-2020 | |
| Exact Sciences Corporation | $105.77 | 2023-2025 | Cologuard Collection Kit |
| Insulet Corporation | $99.80 | 2024-2025 | Omnipod |
| Abbvie INC. | $88.63 | 2023-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $86.67 | 2022-2025 | |
| Dexcom, INC. | $69.10 | 2021-2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.45 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $54.19 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $51.36 | 2019-2021 | |
| Astellas Pharma US INC | $37.71 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $34.07 | 2020-2024 | Trintellix |
| Amarin Pharma, INC. | $31.90 | 2020 | |
| Inspire Medical Systems, INC. | $30.53 | 2025 | Inspire |
| Pharming Healthcare, INC. | $23.67 | 2023 | Ruconest |
| Medtronic, INC. | $23.40 | 2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $21.72 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2025 | Xifaxan |
| Organon LLC | $15.94 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.36 | 2023 | Nuzyra |
| Esperion Therapeutics, INC. | $13.08 | 2021 | |
| Cook Medical LLC | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.